Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a global life science tools company that appears to be well-positioned for future growth, with a strong presence in the protein sciences and diagnostics and genomics segments. The company has a diverse customer base and a strong international presence, providing stability and potential for growth. Additionally, Bio-Techne has taken steps to improve profitability by divesting its Exosome Diagnostics business and consolidating its brands. These efforts, combined with the potential for increased demand and margin expansion, make Bio-Techne a promising investment opportunity.

Bears say

Bio-Techne is facing market share headwinds in its protein sciences and diagnostics and genomics segments, as larger companies with comparator offerings are difficult to compete with. The company is also facing challenges in its cell therapy platform due to a decline in orders from two primary customers, resulting in a 50% year-over-year decline in specific order volumes. While management has maintained its full-year guidance for LSD organic growth, it may be difficult to achieve due to continued headwinds and the delayed impact of the cell therapy air pocket.

Bio-Techne (TECH) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Buy based on their latest research and market trends.

According to 10 analysts, Bio-Techne (TECH) has a Buy consensus rating as of Jun 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.